B7H3 CAR T cell therapy - Bellicum Pharmaceuticals
Alternative Names: iC9 CAR T cell therapy - Bellicum Pharmaceuticals; iC9-CAR.B7-H3 T Cell Therapy; iC9-CAR.B7-H3 T cellsLatest Information Update: 05 Aug 2024
At a glance
- Originator Bellicum Pharmaceuticals
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Triple negative breast cancer
Most Recent Events
- 07 Jun 2024 Phase-I clinical trials in Triple-negative-breast-cancer (Second line therapy or greater) in USA (IV) (NCT06347068)
- 26 Apr 2024 Preclinical trials in Triple negative breast cancer in USA (IV) (NCT06347068)
- 23 Apr 2024 Bellicum Pharmaceuticals plans a phase I trial for Triple negative breast cancer in the US (IV) (NCT06347068)